| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043754666 |
| P356 | DOI | 10.1007/S00115-014-4225-1 |
| P698 | PubMed publication ID | 25962344 |
| P50 | author | Michael Platten | Q38799497 |
| P2093 | author name string | U Herrlinger | |
| P2860 | cites work | Angiogenesis in brain tumours | Q36887534 |
| Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion | Q38054472 | ||
| Microenvironmental clues for glioma immunotherapy | Q38194054 | ||
| Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Q40479307 | ||
| Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide | Q43259949 | ||
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. | Q44783246 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas | Q48109352 | ||
| Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma | Q48264845 | ||
| A vaccine targeting mutant IDH1 induces antitumour immunity | Q48649314 | ||
| Bevacizumab does not increase the risk of remote relapse in malignant glioma. | Q55463287 | ||
| EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma | Q24338526 | ||
| Autophagy: a druggable process that is deregulated in aging and human disease | Q26863483 | ||
| A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study | Q27853118 | ||
| An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor | Q28249782 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | Q30661157 | ||
| Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 | ||
| Bevacizumab and daily temozolomide for recurrent glioblastoma | Q33396384 | ||
| Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma | Q33397569 | ||
| A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). | Q33411920 | ||
| Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. | Q33416502 | ||
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial | Q33417361 | ||
| Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma | Q33710967 | ||
| Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study | Q34480536 | ||
| Antiangiogenic therapy for glioblastoma: current status and future prospects | Q34523319 | ||
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma | Q34722415 | ||
| A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma | Q34992535 | ||
| Proximity ligation assay evaluates IDH1R132H presentation in gliomas | Q35056736 | ||
| Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma | Q36544494 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 684, 686-8, 690-1 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Der Nervenarzt | Q15446312 |
| P1476 | title | [Treatment of the glioma microenvironment]. | |
| P478 | volume | 86 |
Search more.